# A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

> **NCT02825563** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT02825563
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2018-08-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825563, "A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02825563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*